GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Corp (FRA:X0M1) » Definitions » Short Percentage of Float

XOMA (FRA:X0M1) Short Percentage of Float


View and export this data going back to 1986. Start your Free Trial

What is XOMA Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of XOMA's Short Percentage of Float

For the Biotechnology subindustry, XOMA's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XOMA's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XOMA's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where XOMA's Short Percentage of Float falls into.


XOMA (FRA:X0M1) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Corp (FRA:X0M1) » Definitions » Short Percentage of Float
Comparable Companies
MRSN PSTX XERS AGEN INO MGNX EPIX RVNC INZY CRMD OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
XOMAO.PFD:USA XOMAP.PFD:USA XOMA:USA
Address
2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
Website
https://www.xoma.com
XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

XOMA (FRA:X0M1) Headlines

No Headlines